Work

Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.579

Authors: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer N. Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Thomas Olencki, Jamal Christo Tarazi, Brad Rosbrook, Kathrine C. Fernandez, Mariajose Lechuga, Toni K. Choueiri

Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Fox Chase Cancer Center, Vanderbilt University Medical Center, Moffitt Cancer Center, Beth Israel Deaconess Medical Center, The Barbara Ann Karmanos Cancer Institute, Roswell Park Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Pfizer (United States), Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791389181

Cites:

Cited by: 11

Related to: 10